ENDRA Life Sciences Inc
NASDAQ:NDRA
ENDRA Life Sciences Inc
Inventory
ENDRA Life Sciences Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
Inventory
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Inventory
$3.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Inventory
$2.9B
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Stryker Corp
NYSE:SYK
|
Inventory
$5.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Inventory
$6.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Inventory
$1.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
24%
|
CAGR 10-Years
27%
|
|
ENDRA Life Sciences Inc
Glance View
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
See Also
What is ENDRA Life Sciences Inc's Inventory?
Inventory
0
USD
Based on the financial report for Sep 30, 2025, ENDRA Life Sciences Inc's Inventory amounts to 0 USD.
